

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

02 Jun 2026

### Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy

#### Protocol summary

##### Study aim

The effect of oral erythropoietin on oral nutrition tolerance, prevention of complications and reduction of mortality in neonates with ischemic hypoxic encephalopathy

##### Design

Affected infants will be randomly divided into control and intervention groups. The intervention group will include infants who will be given oral erythropoietin at a dose of 400 units / kg daily within the first 48 hours of birth and for 5 days. The control group will receive standard asphyxia and placebo treatments. Normal saline will be given as a placebo in the same amount of oral or gastric catheter. Finally, the two groups in terms of oral feeding tolerance (feeding start time, 100 cc / kg full feeding time) will be considered as the primary outcome.

##### Settings and conduct

Neonates with a gestational age greater than and equal to 37 weeks (semesters and near semesters) and without structural anomalies during 1400-1699 in NICU of Imam Reza Hospital with HIE (ischemic hypoxic encephalopathy) grade 2 or 3, which is based on clinical and laboratory criteria.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Gestational age more than or equal to 37 weeks, perinatal asphyxia, grade 2 and 3 encephalopathy Exclusion criteria: Birth weight <2200 g, A genetic or congenital disease that affects nerve growth or requires multiple surgeries, Head circumference <30 cm, Polycythemia, The infant should participate in another intervention period during hospitalization, Asphyxia cases without HIE, Metabolic diseases, Confirmed infection

##### Intervention groups

The intervention group will include infants who will be given oral erythropoietin ampoules at a dose of 400 units / kg daily within a maximum of 48 hours of birth and will

be prescribed for 5 days.

##### Main outcome variables

The two groups in terms of oral feeding tolerance (feeding start time, time to complete feeding 100 cc / kg) as primary outcome will be considered

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20140907019076N2**

Registration date: **2021-06-19, 1400/03/29**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-06-19, 1400/03/29**

Update count: **0**

##### Registration date

2021-06-19, 1400/03/29

##### Registrant information

##### Name

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 915 261 7030

##### Email address

saeedir@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-06-21, 1399/04/01

##### Expected recruitment end date

2021-07-23, 1400/05/01

##### Actual recruitment start date

empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy

**Public title**  
Effect of Oral Erythropoietin in neonatal with hypoxic ischemic encephalopathy

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Gestational age more than and equal to 37 weeks  
prenatal asphyxia Grade 2 and 3 encephalopathy  
Conscious consent of parents  
**Exclusion criteria:**  
Birth weight <2200 g A genetic or congenital disease that affects nerve growth or requires multiple surgeries  
Head circumference <30 cm Polycythemia The infant should participate in another intervention period during hospitalization Asphyxia cases without HIE Metabolic diseases Confirmed infection

**Age**  
From **1 day** old to **30 days** old

**Gender**  
Both

**Phase**  
1

**Groups that have been masked**

- Participant
- Outcome assessor

**Sample size**  
Target sample size: **100**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
The study design is done in parallel in which the two groups are compared over time. The simple randomization method is using a table of random numbers using the site [www.randomization.com](http://www.randomization.com). Concealment is done through sealed envelopes. The method of the envelope is that the envelopes will be prepared and printed by a member of the research team and random numbers with the help of [Randomaize.com](http://Randomaize.com) and placed inside the envelope. The lid of the envelope will be closed and its contents will not be visible from the outside. Then, the purpose of the study is first explained to the person who meets the conditions, and the person, if he wishes, signs the informed consent form and takes an envelope, and then opens it and enters the intervention or control group based on the contents of the envelope.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**

The subjects and evaluators will be unaware of the intervention and control groups

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

**Secondary Ids**  
empty

**Ethics committees**

**1**

**Ethics committee**  
**Name of ethics committee**  
Ethics committee of Mashhad University of Medical Sciences  
**Street address**  
Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street  
**City**  
Mashhad  
**Province**  
Razavi Khorasan  
**Postal code**  
9138813944

**Approval date**  
2020-08-18, 1399/05/28

**Ethics committee reference number**  
IR.MUMS.MEDICAL.REC.1399.342

## Health conditions studied

**1**

**Description of health condition studied**  
Ischemic hypoxic encephalopathy

**ICD-10 code**  
P91.6

**ICD-10 code description**  
Hypoxic ischemic encephalopathy [HIE]

## Primary outcomes

**1**

**Description**  
Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy

**Timepoint**  
In the erythropoietin intervention group, orally within the first 48 hours of birth at a dose of 400 units per kilogram daily for 5 days (days 7,5,3,1,2)

**Method of measurement**  
By mouth or stomach catheter

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Erythropoietin is administered orally within the first 48 hours of birth dose 400 units per kg daily for 5 days (days 7, 5, 3, 1, 2) in addition to standard treatment for newborns.

#### Category

Placebo

### 2

#### Description

Control group: newborns receive standard asphyxia treatment, including fluid restriction and placebo. The normal saline placebo will be given in the same amount as the oral or gastric catheter.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Imam Reza Hospital

##### Full name of responsible person

Saeedeh Eshkil

##### Street address

Neonatal Intensive Care Unite, Imam Reza Hospital, Ibn Sina Ave, Mashhad, Iram

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9137913316

##### Phone

+98 51 3852 1121

##### Email

eshkils@mums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Mohsen Tafaghodi

##### Street address

Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah Street

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9137913316

##### Phone

+98 51 3852 1121

##### Email

ramresearch@mums.ac.ir

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Mashhad University of Medical Sciences

##### Proportion provided by this source

100

##### Public or private sector

Public

##### Domestic or foreign origin

Domestic

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Saeedeh Eshkil

##### Position

neonatology

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Pediatrics

##### Street address

Neonatal intensive care unite, Imam reza hospital, Ibn Sina Ave, Mashhad, Iran

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9137913316

##### Phone

+98 51 3852 1121

##### Email

eshkils@mums.ac.ir

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Saeedeh Eshkil

**Position**

Neonatology

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Neonatal intensive care unite, Imam Reza Hospital,  
Ibn Sina Ave, Mashhad, Iran

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9137913316

**Phone**

+98 51 3852 1121

**Email**

eshkils@mums.ac.ir

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Saeedeh Eshkil

**Position**

neonatology

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Neonatal Intensive Care Unite, Imam Reza Hospital,  
Ibn Sina Ave, Mashhad, Iran

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9137913316

**Phone**

+98 51 3852 1121

**Email**

eshkils@mums.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

All data can be shared after patients are made unidentifed.

**When the data will become available and for how long**

Data can be accessible 6 months after results are published

**To whom data/document is available**

data can be accessible through an email to the corresponding author

**Under which criteria data/document could be used**

Data will be available for researchers in universities and other scientific institution.

**From where data/document is obtainable**

After sending a request email to the corresponding author, data will be sent in 1 month.

**What processes are involved for a request to access data/document**

Carrying out analysis on data is permitted

**Comments**